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Abstract
Background: Colorectal cancer is the third most frequently diagnosed cancer and the third cause of cancer deaths
in the United States. Despite the fact that tumor cell-intrinsic mechanisms controlling colorectal carcinogenesis have
been identified, novel prognostic and diagnostic tools as well as novel therapeutic strategies are still needed to
monitor and target colon cancer progression. We and others have previously shown, using mouse models, that the
extracellular matrix (ECM), a major component of the tumor microenvironment, is an important contributor to
tumor progression. In order to identify candidate biomarkers, we sought to define ECM signatures of metastatic
colorectal cancers and their metastases to the liver.
Methods: We have used enrichment of extracellular matrix (ECM) from human patient samples and proteomics to
define the ECM composition of primary colon carcinomas and their metastases to liver in comparison with normal
colon and liver samples.
Results: We show that robust signatures of ECM proteins characteristic of each tissue, normal and malignant, can
be defined using relatively small samples from small numbers of patients. Comparisons with gene expression data
from larger cohorts of patients confirm the association of subsets of the proteins identified by proteomic analysis
with tumor progression and metastasis.
Conclusions: The ECM protein signatures of metastatic primary colon carcinomas and metastases to liver defined
in this study, offer promise for development of diagnostic and prognostic signatures of metastatic potential
of colon tumors. The ECM proteins defined here represent candidate serological or tissue biomarkers and potential
targets for imaging of occult metastases and residual or recurrent tumors and conceivably for therapies.
Furthermore, the methods described here can be applied to other tumor types and can be used to investigate
other questions such as the role of ECM in resistance to therapy.
Keywords: Extracellular matrix, Proteomics, Colorectal cancer, Metastasis, Tumor microenvironment, Matrisome
Background
With more than 140,000 new cases diagnosed in 2012,
colorectal cancer is the third most commonly diagnosed
cancer type in both men and women in the United
States. Thanks to prevention and, particularly, early de-
tection, there has been a steady decrease in the number
of deaths due to colorectal cancer over the last two de-
cades. And yet, in 2012 it was estimated that colorectal
cancer would claim the lives of 50,000 patients. Several
genes have been directly implicated in the etiology of colo-
rectal cancer and, despite the fact that tumor-intrinsic
molecular mechanisms controlling colorectal carcinogen-
esis have been identified [1,2], novel prognostic and diag-
nostic tools as well as novel therapeutic strategies are still
needed to prevent colon cancer progression.
Proteomics has become a method of choice to identify
cancer-related biomarkers [3]. Within the last five years,
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global proteomics techniques to the study of colorectal
samples from patients (reviewed in [4,5]). These studies
revealed a certain number of proteins (including extracel-
lular matrix proteins, see Results and discussion section)
up or down-regulated in cancer samples as compared with
normal samples, which represent potential biomarkers.
However, as discussed in the review by De Wit and col-
leagues, these studies have not yet been successfully trans-
lated to the clinic [4].
The extracellular matrix (ECM) is a complex meshwork
of cross-linked proteins providing architectural support
for cells. In addition, ECM proteins bind and present
growth factors to cells, thus providing both biophysical
and biochemical cues that are major regulators of cellular
behavior [6,7]. The ECM is a major component of the
tumor microenvironment and exerts many roles during
tumor progression: it supports proliferation and survival
of tumor cells; it contributes to the formation of the
cancer stem cell niche and thus sustains primary tumor
growth; it participates by its nature and/or architecture in
the formation of a pro-invasive environment; and, finally,
it contributes to the invasion of distant sites by participat-
ing in the formation of a microenvironment that will
support tumor cell seeding and growth [8-10]. Classical
pathology has used excessive ECM deposition (desmopla-
sia) as a marker of tumors with poor prognosis long be-
fore the composition and the complexity of the ECM was
even uncovered. Recent studies have also suggested that
the ECM can act as a barrier to drug delivery and can con-
fer chemo-resistance to tumors [11,12]. The ECM thus
appears of great interest for discovery of ways to predict,
diagnose and cure cancer.
In order to characterize the ECM composition of tu-
mors, we have developed a proteomics-based approach
and have shown, using mouse models, that we can iden-
tify 100–150 ECM proteins in any given tissue or tumor
sample [13]. Using human melanoma and mammary car-
cinoma xenograft models, we have demonstrated that
tumors of different metastatic ability differ in both tumor-
and stroma-derived ECM components [13,14]. Moreover,
we showed that several tumor-derived ECM proteins,
characteristic of highly metastatic tumors, play important
causal roles in metastatic dissemination [14].
Having developed these systematic methods, we now
wished to analyze the composition of the ECM of human
patient samples. We report here the characterization of
the ECM composition of metastatic colorectal cancer
samples (both primary tumors and metastases to liver)
and paired normal tissues (normal colon and liver tissue).
We have been able to identify consistent changes in the
ECM of i) colon tumors as compared with normal colon
ECM; ii) primary tumors as compared with metastases de-
rived from them. Based on these changes, we derived
ECM protein signatures of primary colon carcinoma and
primary colon tumor metastasis to liver. Comparisons of
these signatures with available clinical gene expression
array data show that subsets of these signatures correlate
well with tumor progression and metastasis. We believe
that these data sets will lead to the identification of more
precise predictive signatures and to the development of
assays, in particular serological measurements or immu-
nohistochemical assays, which could be used by patholo-
gists to improve cancer patient management and care.
Methods
Patient samples
For each of the three patients included in this study, we
obtained a set of three samples: normal colon, colon
t u m o ra n di t sm e t a s t a s i st ol i v e r .N o n eo ft h ep a t i e n t s
had received chemotherapy prior to surgery and sample
collection and were all diagnosed with stage IV meta-
static colon cancer. When available, we obtained dupli-
cate samples of some tissues. Samples were between
25 mg and 85 mg. To obtain enough material to
characterize the composition of the normal liver ECM,
we generated two pools of samples from 4 and 5 healthy
patients respectively (reaching a total of approximately
450 mg per pool). Informed consent was obtained from
all of the patients and none of the specimens came from
minors. The anonymized specimens were obtained from
the MGH tissue bank and were removed for medical
reasons unrelated to this project. The specimens were
analyzed in accordance with a protocol approved by the
Massachusetts General Hospital’s Institutional Review
Board (IRB).
Tissue preparation and ECM protein enrichment
The tissue and tumor samples were homogenized with a
Bullet Blender (Next Advance, Averill Park, NY) according
to the manufacturer’s instructions. Sequential extractions
of frozen samples of tumors were performed using the
CNMCS compartmental protein extraction kit (Millipore,
Billerica, MA) as previously described [13]. In brief, fro-
zen samples were homogenized and extracted sequen-
tially to remove preferentially (1) cytosolic proteins, (2)
nuclear proteins, (3) membrane proteins, (4) cytoskel-
etal proteins leaving a final insoluble fraction enriched
for ECM proteins, although different tissues behave
somewhat differently in the ease of extraction so that
proteins sometimes appear in more than one fraction.
The effectiveness of extraction of specific proteins was
monitored by immunoblotting using the following anti-
bodies: rabbit anti-collagen I, mouse anti-GAPDH and
rabbit anti-histones (Millipore, Billerica, MA), the rabbit
anti-actin antibody (serum 14–1) was generated in our
laboratory.
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spectrometry
The ECM-enriched samples were solubilized in urea,
reduced, digested with PNGaseF, Lys-C, and trypsin as
previously described [13]. The resulting peptides (~50
μg) were separated into 11 fractions by off-gel electro-
phoresis (OGE) according to isoelectric point over a pH
range of 3–10 [13]. Each OGE fraction was analyzed by
LC-MS/MS with an LTQ Orbitrap XL mass spectrom-
eter (Thermo Fisher Scientific, San Jose, CA). Mass
spectra were interpreted with Spectrum Mill. MS/MS
s p e c t r aw e r es e a r c h e da g a i n s taU n i P r o td a t a b a s ec o n -
taining human (78,369 entries) sequences downloaded
from the UniProt web site on June 30, 2010 with a set of
common laboratory contaminant proteins (73 entries)
appended. Peptides identified with a false discovery
rate < 1.6% were assembled into identified proteins, and
annotated as being ECM-derived or not as previously
described [13]. Detailed information is provided as
Additional file 1: Supplementary Methods. The raw
mass spectrometry data have been deposited in the pub-
lic proteomics repository MassIVE (http://massive.ucsd.
edu) using the identifier: MSV000078555. The data
should be accessible at ftp://MSV000078555:a@massive.
ucsd.edu.
Gene Set enrichment analysis
Gene Set Enrichment Analysis was performed using
GSEA v2.0.12 (http://www.broadinstitute.org/gsea). We
identified four clinical gene expression datasets which
reported measurements on both primary colon tumors
and metastases to liver. The sample type was used to
define phenotypic classes for comparison. Probe sets
were collapsed to unique gene symbols. Gene sets corre-
sponding to the proteins in our ECM signatures of pri-
mary metastatic colon tumors (37 genes) or metastases
to liver (7 genes) were created and the distributions of
the genes for each of these signatures against the rank-
ordered metastasis vs. primary colon tumor comparisons
were characterized using GSEA with the default settings.
A positive normalized enrichment score indicates en-
richment in metastasis samples. A negative normalized
enrichment score indicates enrichment in primary colon
tumor samples. Each gene in the proteomics-derived
gene set is ordered by its position in the ranked list of
genes from the dataset and is assigned a rank metric
score reflecting its position and the number of probes in
the expression dataset. The leading-edge subsets of genes
are those genes that appear in the ranked list before (for
positive enrichment scores) or after (for negative enrich-
ment scores) the point at which the running sum reaches
its maximum deviation from zero. The leading-edge sub-
set can thus be interpreted as the core that accounts for
the gene set’s enrichment signal. Note that the analysis
includes only those genes in the gene set that are also in
the expression dataset. The raw GSEA data may be down-
loaded from: http://rowley.mit.edu/Hynes/Naba_GSEA_
ColonCancer/.
Results and discussion
Proteomic analyses of ECM from normal tissues and
tumors from colorectal patient samples
We obtained from Massachusetts General Hospital’s tis-
sue bank patient-matched metastatic colorectal cancer
samples (primary tumor and paired metastases to liver)
and normal colonic tissue from three patients. We also
obtained normal liver tissue from healthy donors (see
Methods). ECM proteins were enriched from normal
tissues or tumors using the subcellular fractionation
protocol previously described [13]. Figure 1A shows the
efficiency of the sequential extraction protocol leading to
significant enrichment of collagen I (other ECM proteins
were similarly retained in the final insoluble fraction;
data not shown) and concomitant depletion of intracel-
lular proteins (actin, GAPDH, histones) in the final
ECM-enriched samples.
The composition of the ECM-enriched fractions ob-
tained was subsequently characterized by mass spec-
trometry. The complete proteomic data sets and the
matrisome subsets (ECM and ECM-associated proteins)
are presented in Additional files 2 and 3.
Evaluation of intra-patient reproducibility
To evaluate the reproducibility of our approach, we con-
ducted analyses on two distinct pieces from each tissue
or tumor from patient 1 (Figure 1B-D). We observed good
overlap between the ECM proteins detected in each of the
duplicate samples analyzed. This was true not only for the
duplicate normal colon samples analyzed (Figure 1B) but
also for the duplicate colon tumor samples (Figure 1C)
and the duplicate metastasis samples (Figure 1D). We ob-
served similar reproducibility for normal colon and colon
tumor samples from patient 2 (Additional file 4). Of note,
we had observed similar results from normal murine lung
and colon tissues [13]. These results argue against signifi-
cant intra-tumoral heterogeneity detectable at this level of
analysis; it appears that the sample size (25-85 mg of tis-
sue) was sufficient to average out any spatial heterogeneity
in the ECM. It is also worth noting that we detected more
ECM proteins in the tumor samples (primary colon tumor
and metastasis to liver) than in the normal colon samples,
which may reflect the desmoplasia that often accompanies
tumor progression.
Comparison of the ECM composition of tissues and
tumors across different patients
We next wanted to compare the ECM composition of
samples (normal tissues or tumors) from different patients.
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additional patients and compared the compositions of
the ECM of normal colon (Figure 2A), primary colorec-
tal tumor (Figure 2B), and metastases to liver (Figure 2C)
with the data obtained for patient 1. When we com-
pared the ECM composition of the normal colon sam-
ples from three patients, we identified a set of 89 ECM
proteins present in all three samples (Figure 2A). In
addition we identified subsets of proteins present in two
out of three samples (representing 10% to 12% of the
proteins) and, finally, about 12% of the ECM proteins
detected were patient-specific. The comparison of three
primary metastatic colorectal tumor samples from three
patients revealed that, again, the majority of proteins
detected were found in all three samples (122 proteins;
Figure 2B). We also identified subsets of proteins present
in two out of three samples and finally, depending on the
sample, 8% to 15% of the ECM proteins detected were
patient-specific. The inter-patient variability was greater
for the metastasis samples (Figure 2C). Although we de-
tected a set of 71 proteins common to all three metastasis
samples analyzed, the number of ECM proteins detected
in the metastasis from patient 1 was twice the number de-
tected in patient 2 and 1.5 times the number of proteins
Figure 1 ECM protein enrichment from tissues and tumors and reproducibility of the proteomic analysis. A. The ECM protein enrichment
and sequential extraction of intracellular components (steps 1 to 4) were monitored in each sample (normal colon, colon tumor, metastasis to
liver and normal liver) by immunoblotting for collagen I (ECM marker), actin (cytoskeletal marker), GAPDH (cytosolic marker), and histones (nuclear
marker). The insoluble fraction remaining after serial extraction was enriched for ECM proteins and largely depleted for intracellular components.
B-D. Intra-patient reproducibility was assessed by comparing the ECM compositions of two distinct pieces of the same normal colon (B), primary
colon tumor (C) or metastasis to liver (D) from patient 1. Venn diagrams show the intra-patient reproducibility in terms of matrisome proteins.
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alyzed, we observed a striking overlap, although it is worth
noting that the inter-patient overlap is notably greater for
normal colon samples than it is for colon tumor and
metastasis samples, which may reflect the heterogeneity
among tumor samples (primary tumors or metastases) as
compared with normal tissues (see Conclusions).
Because of the very small amount of extracellular matrix
in the normal liver, we were not able to analyze reliably
the liver ECM from individual patient samples (on average
50 – 75 mg). Instead, and because of the high inter-
patient overlap observed with normal colon samples, we
generated two pools of normal liver samples from healthy
donors (pools were composed of 4 and 5 liver samples, re-
spectively, and were approximately 450 mg each). ECM
proteins could successfully be enriched from these pooled
liver samples (Figure 1A). Moreover, this strategy allowed
us to obtain enough ECM material to be analyzed by mass
spectrometry. We identified 115 and 174 ECM proteins in
each pool, and 105 of them were detected in both pools
(Figure 2D).
After evaluating the similarity among samples obtained
from different patients, we wanted to compare the ECM
compositions of normal tissues with those of primary and
secondary tumors. We therefore defined, for each tissue
or tumor type, its “matrisome” as the ensemble of proteins
detected in at least two of the three patients studied.
According to this definition, the matrisome of normal hu-
man colon comprises 122 proteins, the matrisome of pri-
mary colon tumors 187 proteins and the matrisome of
metastases 135 proteins (grey areas in Figure 2A-C). To
define the normal liver matrisome, we took the intersec-
tion (105 proteins) of the two pools analyzed (Figure 2D).
We further subdivided each matrisome list into the
protein categories we previously defined [13,15]: ECM
glycoproteins, collagens and proteoglycans for core
matrisome proteins and ECM-affiliated proteins, ECM
regulators and secreted factors for ECM-associated pro-
teins (Figure 3) [13,15].
Definition of signatures of metastatic colorectal cancer
and associated metastasis to liver
The comparison of the matrisome compositions of
normal tissues (colon and liver) and colorectal tumors
(primary tumors and metastases) revealed that a large
fraction of proteins (69) are ubiquitously expressed and
detected in all four tissue types (Figure 2E, Figure 3).
We observed that half of the glycoproteins detected
(Figure 3A) as well as most of the collagens (Figure 3B)
and proteoglycans (Figure 3C) are common to the four
tissue types. Components associated with the extracellu-
lar matrix, such as ECM regulators (that include ECM
remodeling enzymes) or ECM-affiliated proteins and
ECM-associated secreted factors (growth factors, cyto-
kines etc.) are present at lower abundance in the ECM-
rich samples (Additional file 2B) and are, for the most
part, restricted to certain tissues (Figure 3, Additional
file 2B). This comparison also revealed that the ECM
composition of metastases to liver resembles more the
ECM of primary colorectal tumors than that of normal
liver. Importantly, we identified subsets of tumor-specific
proteins: 37 proteins were characteristic of the colon
tumor matrisome, 7 proteins were characteristic of the
metastasis matrisome and 23 proteins were characteristic
of both primary tumors and metastases (Figure 2E,
Figure 3, and Additional file 2C).
Gene Set enrichment analyses identify subsets of
ECM-encoding genes strongly correlated with primary
colon tumors or their metastases to liver
We next sought to explore potential correlations be-
tween our data and other clinical data sets. Accordingly,
we used Gene Set Enrichment Analysis [16] to evaluate
the relationship between the proteomics-derived ECM
signatures for i) colon primary tumors and ii) metastases
(Figure 2E, Figure 3; see Methods for further details)
and microarray-based gene expression studies involving
large cohorts of patients. The four relevant clinical gene
expression data sets analyzed [17-20] represent a total of
289 primary colon tumor samples and 120 metastasis
samples (Additional file 5). Comparisons were set up be-
tween colon tumor metastases to liver and primary tumor
samples; hence a positive enrichment score will indicate
enrichment in metastasis samples and a negative enrich-
ment score, enrichment in primary colon tumor samples
(Figure 4A,B and Additional file 5). The distributions of
genes in our two signatures within these comparisons
were characterized with GSEA and we consistently
(See figure on previous page.)
Figure 2 Definition and comparison of the matrisomes of the metastatic colon cancer and control tissue. A-C. Venn diagrams show the
numbers of ECM proteins overlapping among the ECM-enriched fractions of the three patients’ normal colons (A), primary colon tumors (B) and
metastases to liver (C), respectively. For patients for whom we analyzed duplicate samples of the same tissue or tumor, we chose the sample with
the most abundant ECM protein content (see Additional file 2). We define the matrisome of a given tissue as the ensemble of proteins detected
in at least two out of the three patients (grey). D. Venn diagram shows the number of proteins overlapping between the ECM of two pools
composed of 4 and 5 normal liver samples respectively. The normal liver matrisome is composed of 105 proteins (grey). E. Venn diagram shows
comparisons among the metastatic colon cancer matrisomes (primary colon tumor and associated metastases to liver) and control tissue
matrisomes (normal colon and normal liver). ECM signatures of primary metastatic colon tumors and associated metastases are listed (see also
Additional file 2C).
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in their corresponding phenotypic classes in the gene
expression experiments. The metastasis signature was
consistently enriched in the metastasis samples in all
four comparisons, with enrichment scores ranging be-
tween 1.112 and 1.815 (Figure 4A, Additional file 6, left
panels). The colon cancer signature set was enriched in
the colon cancer class in all four comparisons, with
enrichment scores ranging from −0.876 and −1.481
(Figure 4B, Additional file 6, right panels).
Next, we evaluated which of the genes from our ECM
signatures consistently ranked most highly with regard
to class association by comparing the composition of the
various leading edge sets (Figure 4C,D, see Methods).
Despite the fact that it is well known that protein levels
do not necessarily correlate with mRNA levels and one
would not expect one-to-one concordance, we identified
a subset of three out of the seven genes from the metasta-
sis signature (HPX, SPP1 and COMP) that were closely
associated with the metastasis class in three out of the
four clinical expression datasets (Figure 4C). We also
identified a subset of four genes from the primary colon
tumor signature (MMP1, MMP2, MMP11, and LEFTY1)
that was associated with the colon cancer class in at least
three out of the four clinical expression datasets tested
(Figure 4D). An additional six genes (EMID1, MMP12,
LEPRE1, MFGE8, MMP9 and FMOD) were strongly asso-
ciated with primary colon cancers in two out of four clin-
ical gene expression data sets. A recent gene expression
profiling study by Lin and colleagues also identified osteo-
pontin (SPP1, Secreted Phospho-Protein1) as being up-
regulated in colorectal liver metastases as compared to
primary tumors and normal liver, in accordance with our
data [21]. The same study also identified SPARC (Secreted
Protein Acidic and Rich in Cysteine or osteonectin) in
colorectal metastases to liver whereas we have detected
SPARC mostly in primary colorectal tumors and only in
the metastasis of one patient; our results agree concerning
the absence of SPARC in normal liver [21]. Periostin has
also been reported to be associated with colon cancer
metastasis [22,23]; we detected this protein in all the tis-
sue samples studied – it was not specific to malignant
tissue but that does not rule out a role in malignant pro-
gression. Of note, SPP1, SPARC and periostin have all
been implicated in other types of metastatic cancer and
are often invoked as possible biomarkers of aggressive
tumor types [24-27].
In addition to these concordances with clinical gene
expression data, our proteomics-based discovery pipeline
identified other proteins that are potential serological
biomarkers for colorectal cancer patients: a recent study
by Yao and colleagues [28] identified EFEMP2 (EGF-con-
taining fibulin-like extracellular matrix protein 2 or Fibu-
lin 4) and thrombospondin 2 (THBS2) as a potential
biomarkers detected in the serum of colorectal cancer
patients. In accord with these data, we detected both
EFEMP2 and THBS2 in both primary and secondary
colon tumors but not in normal tissues. Another example
is Tissue Inhibitor of Metalloproteinase-1 (TIMP1), de-
tected in both primary metastatic tumors and metastases
to liver in our study, and previously found to be elevated
in the serum of colorectal cancer patients and proposed to
be not only a good diagnostic factor but also a good pre-
dictor and indicator of response to chemotherapy [29,30].
Both EFEMP2 and TIMP1 are also proposed to be of
superior value than carcinoembryonic-antigen (CEA), the
only biomarker currently used to diagnose and monitor
the treatment of colorectal cancer patients [31].
Conclusions
We demonstrate in this study that we can characterize
in detail the composition of the extracellular matrix of
normal tissues and tumors using small samples from hu-
man colorectal cancer patients. We show that our prote-
omics approach can robustly define the matrisomes of
tumors and matched normal samples. Based on this ana-
lysis, we established ECM signatures characteristic of pri-
mary metastatic colorectal tumors and their metastases to
liver. Further work is needed to determine whether the
proteins identified in our study play any functional roles
in colorectal tumor progression and metastasis. Future
work will aim to characterize the ECM composition of
poorly metastatic tumors and of tumors and metastases
that do or do not respond to chemotherapy.
Although we focused here on proteins common to the
three patients studied, it is worth noting that we also
identified patient-specific sets of ECM proteins (white
areas of the Venn diagrams presented in Figure 2). We
(See figure on previous page.)
Figure 3 Comparison of the metastatic colon cancer matrisomes and control tissue matrisomes. Proteins included in this table were
detected in at least two of the three patients for normal colon, colon tumor and metastasis samples, or in both pools of normal liver samples
(see grey areas in Figure 2A-D). The proteins are subdivided into categories constituting the matrisome as follows: the core matrisome includes
structural proteins such as ECM glycoproteins (A), collagens (B) and proteoglycans (C). In addition we defined three categories of ECM-associated
proteins that are present at lower molar ratios: ECM regulators include ECM remodeling enzymes (crosslinking enzymes, proteases and their
regulators; D), ECM-affiliated proteins (E) and ECM-associated secreted factors (including growth factors, cytokines, etc.; F) Dash (−) indicates that
the protein was not designated part of the matrisome of a given tissue (although in some instances, the protein was detected in one patient
only, see Additional file 2B,C and Conclusions).
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of the tumors (particular region sampled, stage, etc.) that
is beyond the scope of this study to determine due to
the small number of tumors examined. Nonetheless, one
can postulate that within the signatures defined here are
sets of ECM proteins that could serve as novel bio-
markers of metastatic potential in primary tumor biop-
sies and could, furthermore, be used to detect small
disseminated metastases that remain undetected by
current imaging methods. In order to test these postu-
lates, one needs screening of larger cohorts of patients
for presence or absence of these ECM proteins. Our ini-
tial comparisons between the ECM protein signatures
and mRNA expression datasets support the correlation
with metastatic progression of some of the proteins de-
fined – others may well correlate when examined at the
protein level (e.g., by immunohistochemistry of tumor tis-
sue microarrays or by serological measurements). ECM
proteins are particularly favorable candidate biomarkers
since they are abundant, are laid down in characteristic
patterns and are readily accessible. ECM protein levels may
indeed be more appropriate indicators of tumor properties
than mRNA levels since proteins are the operative mol-
ecules in the tumor microenvironment and changes
occur at that level that are not reflected at the mRNA
level because of post-transcriptional processes (transla-
tion, stability etc.).
Methods developed by others have already been used ef-
fectively to target tumor vascular-specific ECM proteins
(splice variants of fibronectin or tenascin) for use in im-
aging tumors and metastases in mouse models and pa-
tients and also for targeting isotopes, drugs and cytokines
to tumors for therapeutic applications [32]. A recent study
demonstrated that administration of interleukin 12 coupled
to an antibody directed against a tumor-specific spliced
isoform of fibronectin (a major ECM protein) led to the re-
gression of various tumors including subcutaneous CT26
colon carcinoma tumors [33]. Such approaches could pro-
vide sorely needed new strategies for the treatment and
management of metastatic colon cancers and we hope that
the definition of larger numbers of ECM biomarkers will
contribute to improvements in colon cancer patients’ diag-
nosis, prognosis, treatment and survival.
Availability of supporting data
In addition to the supporting data included as additional
files, the raw GSEA data may be downloaded from:
http://rowley.mit.edu/Hynes/Naba_GSEA_ColonCancer/.
The raw mass spectrometry data accompanying this publi-
cation have been deposited in the public proteomics
repository MassIVE (http://massive.ucsd.edu) using the
identifier: MSV000078555. The data should be access-
ible at ftp://MSV000078555:a@massive.ucsd.edu.
Additional files
Additional file 1: Supplementary Methods related to the Proteomic
analysis of ECM-enriched samples.
Additional file 2: A. Complete proteomics data set. Proteins are
sorted by matrisome divisions (i.e. core matrisome, matrisome
associated or other, column A), matrisome categories (column B) and
overall confidence score (column BS). B. Subset of extracellular matrix
proteins detected in any samples. Data were extracted from Additional
file 2A. C. Abundance of ECM proteins characteristic of metastatic colon
tumors, metastases or metastatic colon tumors and metastases (see
Figure 2E). Numbers represent the abundance of each protein and
correspond to the sum of the abundance across the independent
samples for each protein (calculated from Additional file 2B, columns F,
N and R for normal colon samples; columns V, AD and AL for colon
tumor samples; from columns AT, BB and BF for colon tumor metastasis
to liver samples and columns BJ and BN for normal liver samples). Dash
(−) indicates that the protein was detected in none of the independent
samples. White cells are indicative of proteins that were detected in one
patient only and thus do not qualify to be part of the matrisome of a
given tissue.
Additional file 3: Detailed list of all of the confidently identified
peptide spectrum matches (PSMs) from the LC-MS/MS runs of each
of the normal tissues and tumor samples analyzed. Due to its large
size, the excel file has been deposited in the public proteomics
repository MassIVE and is accessible in the Results directory at ftp://
MSV000078555@massive.ucsd.edu/.
Additional file 4: Intra-patient reproducibility (Patient 2). Venn
diagrams represent the intra-patient reproducibility assessed by comparing
the ECM composition of two distinct pieces of the same colon tumor
(A) or metastasis (B) from patient 2.
Additional file 5: A. List of publicly available clinical gene
expression datasets used for GSEA. B. Values indicate for each gene of
the signatures its rank metric scores (used to build Figure 4C and D).
Additional file 6: GSEA Enrichment Plots. Enrichment plots generated
by comparing the metastasis ECM gene set (left panels) and the primary
metastatic colon cancer gene set (right panels) defined in this study with
four publicly available clinical gene expression data sets (see Additional
file 5).
(See figure on previous page.)
Figure 4 Gene Set Enrichment Analysis. Representative enrichment plot resulting from the comparison of the ECM proteomic signature of
metastasis (A) or the ECM primary metastatic colon tumor signature (B) with the gene expression data set GSE49355 comprising 20 primary
colon adenocarcinoma samples and 19 paired liver metastasis samples. The position of the leading edge is highlighted and the direction of the
correlation indicated. The positions of the ECM signature genes along the class comparison for each gene set are indicated by vertical lines.
C-D .Heat map shows enrichment of the ECM metastasis signature in metastasis microarray samples (C) and of the ECM primary colon cancer
signature in primary colon cancer microarray samples (D). Cells are colored according to the role of those genes in the enrichment based on
their rank metric scores (Additional file 5B). Dark yellow cells indicate genes present in the leading edge of metastasis enrichment; dark blue
indicates genes present in the leading edge of colon cancer enrichment; light blue indicates genes trending toward the colon cancer phenotype
but not part of the leading edge; light yellow indicates genes trending toward the liver metastasis phenotype but not part of the leading edge.
Grey cells indicate genes for which the expression level was not determined.
Naba et al. BMC Cancer 2014, 14:518 Page 10 of 12
http://www.biomedcentral.com/1471-2407/14/518Abbreviations
ECM: Extracellular matrix; LC-MS/MS: Liquid chromatography and tandem
mass spectrometry; OGE: Off-gel electrophoresis.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Conception and design of the experiments: AN, KRC, SAC, KKT, ROH.
Development of proteomics methodology: AN, KRC. Acquisition of data: AN,
KRC. Analysis and interpretation of data: AN, KRC, CAW, ROH. Writing of the
manuscript: AN, KRC, CAW, SAC, KKT, ROH. Study supervision: ROH. All
authors have read and approved the submitted manuscript.
Acknowledgements
The authors wish to thank Dr. Jie Wu from the Barbara K. Ostrom
Bioinformatics and Computing facility at the Swanson Biotechnology Center
for assistance with Gene Set Enrichment Analyses, Dr. John Lamar for critical
reading of the manuscript and the members of the Hynes Lab for helpful
discussions.
Grant support
This work was supported by grants from the National Cancer Institute –
Tumor Microenvironment Network (U54 CA126515/CA163109), the Broad
Institute of MIT and Harvard, the Howard Hughes Medical Institute, of which
ROH is an Investigator and in part by Support Grant to the Koch Institute
(P30-CA14051 from the National Cancer Institute). AN was supported by
postdoctoral fellowships from the Howard Hughes Medical Institute and the
Ludwig Center for Cancer Research.
Author details
1David H. Koch Institute for Integrative Cancer Research, Massachusetts
Institute of Technology, Cambridge, MA 02139, USA.
2Howard Hughes
Medical Institute, Massachusetts Institute of Technology, 02139 Cambridge,
MA, USA.
3Proteomics Platform, Broad Institute of MIT and Harvard, 02142
Cambridge, MA, USA.
4David H. Koch Institute for Integrative Cancer
Research - Barbara K. Ostrom Bioinformatics and Computing facility at the
Swanson Biotechnology Center, 02139 Cambridge, MA, USA.
5Division of
Surgical Oncology, Massachusetts General Hospital Cancer Center, Boston
02114, MA, USA.
Received: 3 March 2014 Accepted: 30 June 2014
Published: 18 July 2014
References
1. Rustgi AK: The genetics of hereditary colon cancer. Genes Dev 2007,
21:2525–2538.
2. Network CGA: Comprehensive molecular characterization of human
colon and rectal cancer. Nature 2012, 487:330–337.
3. Hanash S, Taguchi A: The grand challenge to decipher the cancer
proteome. Nat Rev Cancer 2010, 10:652–660.
4. De Wit M, Fijneman RJA, Verheul HMW, Meijer GA, Jimenez CR: Proteomics
in colorectal cancer translational research: biomarker discovery for
clinical applications. Clin Biochem 2013, 46:466–479.
5. Luo Y, Wang L, Wang J: Developing proteomics-based biomarkers for
colorectal neoplasms for clinical practice: opportunities and challenges.
Proteomics Clin Appl 2013, 7:30–41.
6. Hynes RO: The extracellular matrix: not just pretty fibrils. Science 2009,
326:1216–1219.
7. Hynes RO, Naba A: Overview of the matrisome–an inventory of
extracellular matrix constituents and functions. Cold Spring Harb Perspect
Biol 2012, 4:a004903.
8. Cretu A, Brooks PC: Impact of the non-cellular tumor microenvironment
on metastasis: potential therapeutic and imaging opportunities. J Cell
Physiol 2007, 213:391–402.
9. Egeblad M, Nakasone ES, Werb Z: Tumors as organs: complex tissues that
interface with the entire organism. Dev Cell 2010, 18:884–901.
10. Lu P, Weaver VM, Werb Z: The extracellular matrix: a dynamic niche in
cancer progression. J Cell Biol 2012, 196:395–406.
11. Jacobetz MA, Chan DS, Neesse A, Bapiro TE, Cook N, Frese KK, Feig C,
Nakagawa T, Caldwell ME, Zecchini HI, Lolkema MP, Jiang P, Kultti A,
Thompson CB, Maneval DC, Jodrell DI, Frost GI, Shepard HM, Skepper JN,
Tuveson DA: Hyaluronan impairs vascular function and drug delivery in a
mouse model of pancreatic cancer. Gut 2013, 62:112–120.
12. Chauhan VP, Stylianopoulos T, Boucher Y, Jain RK: Delivery of molecular
and nanoscale medicine to tumors: transport barriers and strategies.
Annu Rev Chem Biomol Eng 2011, 2:281–298.
13. Naba A, Clauser KR, Hoersch S, Liu H, Carr SA, Hynes RO: The matrisome:
in silico definition and in vivo characterization by proteomics of
normal and tumor extracellular matrices. Mol Cell Proteomics 2012,
11:M111.014647.
14. Naba A, Clauser KR, Lamar JM, Carr SA, Hynes RO: Extracellular matrix
signatures of human mammary carcinoma identify novel metastasis
promoters. eLife 2014, 3:e01308.
15. Naba A, Hoersch S, Hynes RO: Towards definition of an ECM parts list: an
advance on GO categories. Matrix Biol 2012, 31:371–372.
16. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA,
Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP: Gene set
enrichment analysis: a knowledge-based approach for interpreting
genome-wide expression profiles. Proc Natl Acad Sci U S A 2005,
102:15545–15550.
17. Del Rio M, Mollevi C, Vezzio-Vie N, Bibeau F, Ychou M, Martineau P: Specific
extracellular matrix remodeling signature of colon hepatic metastases.
PLoS One 2013, 8:e74599.
18. Ki DH, Jeung H-C, Park CH, Kang SH, Lee GY, Lee WS, Kim NK, Chung HC,
Rha SY: Whole genome analysis for liver metastasis gene signatures in
colorectal cancer. Int J Cancer J Int Cancer 2007, 121:2005–2012.
19. Tsuji S, Midorikawa Y, Takahashi T, Yagi K, Takayama T, Yoshida K,
Sugiyama Y, Aburatani H: Potential responders to FOLFOX therapy
for colorectal cancer by random forests analysis. Br J Cancer 2012,
106:126–132.
20. Sheffer M, Bacolod MD, Zuk O, Giardina SF, Pincas H, Barany F, Paty PB,
Gerald WL, Notterman DA, Domany E: Association of survival and disease
progression with chromosomal instability: a genomic exploration of
colorectal cancer. Proc Natl Acad Sci U S A 2009, 106:7131–7136.
21. Lin AY, Chua M-S, Choi Y-L, Yeh W, Kim YH, Azzi R, Adams GA, Sainani K,
van de Rijn M, So SK, Pollack JR: Comparative profiling of primary
colorectal carcinomas and liver metastases identifies LEF1 as a
prognostic biomarker. PLoS One 2011, 6:e16636.
22. Ben Q-W, Zhao Z, Ge S-F, Zhou J, Yuan F, Yuan Y-Z: Circulating levels of
periostin may help identify patients with more aggressive colorectal
cancer. Int J Oncol 2009, 34:821–828.
23. Bao S, Ouyang G, Bai X, Huang Z, Ma C, Liu M, Shao R, Anderson RM,
Rich JN, Wang X-F: Periostin potently promotes metastatic growth of
colon cancer by augmenting cell survival via the Akt/PKB pathway.
Cancer Cell 2004, 5:329–339.
24. Chlenski A, Cohn SL: Modulation of matrix remodeling by SPARC in
neoplastic progression. Semin Cell Dev Biol 2010, 21:55–65.
25. Ahmed M, Behera R, Chakraborty G, Jain S, Kumar V, Sharma P, Bulbule A,
Kale S, Kumar S, Mishra R, Raja R, Saraswati S, Kaur R, Soundararajan G,
Kumar D, Thorat D, Sanyal M, Ramdasi A, Ghosh P, Kundu GC: Osteopontin:
a potentially important therapeutic target in cancer. Expert Opin Ther
Targets 2011, 15:1113–1126.
26. Rangaswami H, Bulbule A, Kundu GC: Osteopontin: role in cell signaling
and cancer progression. Trends Cell Biol 2006, 16:79–87.
27. Liu AY, Zheng H, Ouyang G: Periostin, a multifunctional matricellular
protein in inflammatory and tumor microenvironments. Matrix Biol J Int
Soc Matrix Biol 2014.
28. Yao L, Lao W, Zhang Y, Tang X, Hu X, He C, Hu X, Xu LX: Identification of
EFEMP2 as a serum biomarker for the early detection of colorectal
cancer with lectin affinity capture assisted secretome analysis of
cultured fresh tissues. J Proteome Res 2012, 11:3281–3294.
29. Holten-Andersen MN, Christensen IJ, Nielsen HJ, Stephens RW, Jensen V,
Nielsen OH, Sørensen S, Overgaard J, Lilja H, Harris A, Murphy G, Brünner N:
Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield
high diagnostic sensitivity and specificity in patients with colon cancer.
Clin Cancer Res 2002, 8:156–164.
30. Sørensen NM, Byström P, Christensen IJ, Berglund A, Nielsen HJ, Brünner N,
Glimelius B: TIMP-1 is significantly associated with objective response
and survival in metastatic colorectal cancer patients receiving
combination of irinotecan, 5-fluorouracil, and folinic acid. Clin Cancer Res
2007, 13:4117–4122.
Naba et al. BMC Cancer 2014, 14:518 Page 11 of 12
http://www.biomedcentral.com/1471-2407/14/51831. McPherson RA, Pincus MR: Henry’s Clinical Diagnosis and Management by
Laboratory Methods. 22nd edition. Philadelphia, PA, U.S.A: Elsevier Health
Sciences; 2011.
32. Pasche N, Neri D: Immunocytokines: a novel class of potent armed
antibodies. Drug Discov Today 2012, 17:583–590.
33. Pasche N, Wulhfard S, Pretto F, Carugati E, Neri D: The antibody-based
delivery of interleukin-12 to the tumor neovasculature eradicates murine
models of cancer in combination with paclitaxel. Clin Cancer Res 2012,
18:4092–4103.
doi:10.1186/1471-2407-14-518
Cite this article as: Naba et al.: Extracellular matrix signatures of human
primary metastatic colon cancers and their metastases to liver. BMC
Cancer 2014 14:518.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Naba et al. BMC Cancer 2014, 14:518 Page 12 of 12
http://www.biomedcentral.com/1471-2407/14/518